{"title":"An alkaline phosphatase-activatable photosensitizer based on 2-anthrol for selective targeting of cancer cells","authors":"Yusha Li, Yuki Masuda, Yuzuha Miyazawa, Daisuke Takahashi, Kazunobu Toshima","doi":"10.1016/j.bmcl.2025.130371","DOIUrl":"10.1016/j.bmcl.2025.130371","url":null,"abstract":"<div><div>2-Anthrol (<strong>2</strong>) was found to induce protein degradation under neutral conditions and without the need for additives upon visible light irradiation. Based on this simple and small scaffold, a novel photosensitizer <strong>4</strong> was designed and synthesized, which is specifically activated by the tumor-associated biomarker alkaline phosphatase (ALP). Upon visible light exposure, <strong>4</strong> exhibited selective photo-cytotoxicity toward cancer cells overexpressing ALP, demonstrating its potential as a targeted phototherapeutic agent.</div></div>","PeriodicalId":256,"journal":{"name":"Bioorganic & Medicinal Chemistry Letters","volume":"129 ","pages":"Article 130371"},"PeriodicalIF":2.2,"publicationDate":"2025-08-12","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144854111","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Salma Kwarteng , Jacquelyn Wilhelm , Merna Salama , Monika Salama , Klarissa Hollander , Karen S. Anderson , Nina M. Goodey , Kathleen M. Frey
{"title":"A virtual screening strategy to repurpose antifolate compounds as W. bancrofti DHFR inhibitors","authors":"Salma Kwarteng , Jacquelyn Wilhelm , Merna Salama , Monika Salama , Klarissa Hollander , Karen S. Anderson , Nina M. Goodey , Kathleen M. Frey","doi":"10.1016/j.bmcl.2025.130370","DOIUrl":"10.1016/j.bmcl.2025.130370","url":null,"abstract":"<div><div>Lymphatic filariasis, caused by <em>Wuchereria bancrofti,</em> remains a global health challenge. The enzyme <em>Wuchereria bancrofti</em> dihydrofolate reductase (WbDHFR) is a potential therapeutic target due to DHFR's critical role in folate metabolism and DNA synthesis. In this study, we employed a virtual screening workflow to repurpose antifolate compounds as WbDHFR inhibitors. Using structural data from the Protein Data Bank, we constructed a library of 194 antifolates and docked them to the WbDHFR folate binding site. Compounds methotrexate, TSD001, TSD10, and TSD25, with docking scores ranging from −9 to −8 kcal/mol, were selected for experimental validation. Inhibition assays demonstrated nanomolar activity with methotrexate and low micromolar activity with TSD001 (K<sub>i</sub> = 1 μM). Crystallographic studies revealed high-resolution structures of WbDHFR in complex with methotrexate (2.4 Å), TSD001 (2.9 Å), TSD10 (1.8 Å) and TSD25 (2.1 Å), providing detailed insights into binding interactions. Major interactions common for the inhibitors include hydrogen bonds with Glu32. These findings highlight the effectiveness of the virtual screening workflow and establish a foundation for optimizing these antifolate compounds for WbDHFR inhibition. This workflow can be applied to other parasitic DHFR enzymes, advancing drug discovery efforts against neglected tropical diseases.</div></div>","PeriodicalId":256,"journal":{"name":"Bioorganic & Medicinal Chemistry Letters","volume":"129 ","pages":"Article 130370"},"PeriodicalIF":2.2,"publicationDate":"2025-08-12","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144854110","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Jacinta R. Macdonald , Gillian M. Fisher , Sasha Hayes , Tina S. Skinner-Adams , Rohan A. Davis , Katherine T. Andrews
{"title":"Antiplasmodial activity of tambjamines, dihydro-β-agarofurans and pyrroloazepines derived from Australian plant and marine species","authors":"Jacinta R. Macdonald , Gillian M. Fisher , Sasha Hayes , Tina S. Skinner-Adams , Rohan A. Davis , Katherine T. Andrews","doi":"10.1016/j.bmcl.2025.130369","DOIUrl":"10.1016/j.bmcl.2025.130369","url":null,"abstract":"<div><div>Malaria is a significant cause of morbidity and mortality, with 263 million cases and 597,000 deaths estimated in 2023. While effective drug combinations are available to prevent and treat malaria, <em>Plasmodium</em> parasite drug resistance is compromising all current options. This situation means that new drugs that act on novel <em>Plasmodium</em> drug targets are needed. Natural products, including artemisinin, derived from <em>Artemisia annua</em>, and its derivatives, have been an important source of antimalarials. In this study we investigated a panel of 43 compounds from the NatureBank natural product library for <em>in vitro</em> activity against asexual stage <em>P. falciparum</em> parasites. Four compounds isolated from Australian plant and marine samples were identified with novel antiplasmodial activity - tambjamine F (IC<sub>50</sub> 1.06 μM) and tambjamine C (IC<sub>50</sub> 3.40 μM) from the marine ascidian <em>Sigillina signifera,</em> bilocularin B (IC<sub>50</sub> 2.18 μM) from the rainforest plant <em>Maytenus bilocularis</em> and hymenialdisine (IC<sub>50</sub> 2.90 μM) from the marine sponge <em>Acanthella costata</em>.</div></div>","PeriodicalId":256,"journal":{"name":"Bioorganic & Medicinal Chemistry Letters","volume":"129 ","pages":"Article 130369"},"PeriodicalIF":2.2,"publicationDate":"2025-08-12","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144854112","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Megan M. Voisinet , Caroline M. Palmentiero , Jillian E.M. McKeon , Colm P. Roster , Haley M. Carlson , Thomas D. Brzezinski , Kaylin M. Burton , James C. Morris , R. Adam Mosey
{"title":"Development of dihydroquinazoline compounds as novel therapeutics against Naegleria fowleri","authors":"Megan M. Voisinet , Caroline M. Palmentiero , Jillian E.M. McKeon , Colm P. Roster , Haley M. Carlson , Thomas D. Brzezinski , Kaylin M. Burton , James C. Morris , R. Adam Mosey","doi":"10.1016/j.bmcl.2025.130363","DOIUrl":"10.1016/j.bmcl.2025.130363","url":null,"abstract":"<div><div>Primary amoebic meningoencephalitis (PAM) is a brain infection caused by the free-living amoebae <em>Naegleria fowleri.</em> There are few viable treatment options for the infection, resulting in a >97 % fatality rate. Small molecules are being increasingly investigated as treatment options for this deadly infection. This work details the discovery of a dihydroquinazoline that was toxic to the amoeba and subsequent structure–activity relationship (SAR) development of compounds with increasingly potent activity, yielding several early lead candidates exhibiting submicromolar activity (EC<sub>50</sub> = 0.62–0.84 μM) and limited cytotoxicity (CC<sub>50</sub> > 10 μM).</div></div>","PeriodicalId":256,"journal":{"name":"Bioorganic & Medicinal Chemistry Letters","volume":"129 ","pages":"Article 130363"},"PeriodicalIF":2.2,"publicationDate":"2025-08-11","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144831131","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Zhijie Wu, Changwei Chen, Jian Yan, Peipei Zhu, Min Xiong, Dong Liu, Shaojiang Deng
{"title":"Structure-activity relationship study of HIF-2α inhibitors with tricyclic scaffold","authors":"Zhijie Wu, Changwei Chen, Jian Yan, Peipei Zhu, Min Xiong, Dong Liu, Shaojiang Deng","doi":"10.1016/j.bmcl.2025.130366","DOIUrl":"10.1016/j.bmcl.2025.130366","url":null,"abstract":"<div><div>HIF-2α is a member of the HIF transcription factor family and a key oncogenic driver in renal cell carcinoma, which is characterized by the overaccumulation of HIF-2α protein. Therefore, inhibition of HIF-2α holds therapeutic potential for renal cell carcinoma. Disclosed herein are the discovery and characterization of a novel series of HIF-2α inhibitors with a tricyclic scaffold. A systematic SAR study was performed, and optimization of the tricyclic scaffold demonstrated that a fluorine atom in the cis.</div></div>","PeriodicalId":256,"journal":{"name":"Bioorganic & Medicinal Chemistry Letters","volume":"129 ","pages":"Article 130366"},"PeriodicalIF":2.2,"publicationDate":"2025-08-09","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144820263","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Ganesh Bist , Ahmed Elsheikh , Sewon Kim, Ruea-Yea Huang, Donna Ruszaj, Sukyung Woo , Youngjae You
{"title":"Novel small molecule analogs for advancing apelin receptor antagonism with enhanced plasma and microsomal stability","authors":"Ganesh Bist , Ahmed Elsheikh , Sewon Kim, Ruea-Yea Huang, Donna Ruszaj, Sukyung Woo , Youngjae You","doi":"10.1016/j.bmcl.2025.130367","DOIUrl":"10.1016/j.bmcl.2025.130367","url":null,"abstract":"<div><div>The apelin receptor (APJ), a G protein-coupled receptor, has emerged as a promising therapeutic target in oncology due to its role in tumor growth, angiogenesis, metastasis, and resistance to anti-VEGF therapy. However, ML221, the only reported small-molecule APJ antagonist, exhibits extremely poor plasma (<1 % remaining after 1 h) and liver microsomal (t<sub>1/2</sub> < 1 min) stability, limiting its translational potential. To address this, we designed and synthesized a focused series of ML221 analogs incorporating amide, ether, and sulfonate linkages to block esterase-mediated degradation aiming to improve metabolic stability while maintaining APJ antagonistic activity. Among them, sulfonate-linked analogs <strong>21</strong> and <strong>22</strong> retained strong β-arrestin inhibition (IC<sub>50</sub> = 3.1 μM and 3.2 μM; 90.1 % and 80.1 % inhibition, respectively) while exhibiting significantly enhanced metabolic stability (100 % remaining in plasma after 1 h; liver microsomal t<sub>1/2</sub> = 5 min). These compounds selectively inhibited APJ-overexpressing cancer cells (OVCAR8) and suppressed apelin-induced endothelial cell migration (OVCAR3 and HUVEC), with compound <strong>21</strong> showing the most potent inhibition of cell migration. Overall, this study establishes the sulfonate linkage as a particularly favorable scaffold modification and a metabolically stable ester bioisostere that enhances stability without compromising APJ antagonism. These analogs represent promising candidate for further in-vivo optimization and advancement as next-generation APJ antagonists for cancer therapy.</div></div>","PeriodicalId":256,"journal":{"name":"Bioorganic & Medicinal Chemistry Letters","volume":"129 ","pages":"Article 130367"},"PeriodicalIF":2.2,"publicationDate":"2025-08-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144815436","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Juan Zhang , Le Mi , Zhenwei Wang , Xiaohui Zhang , Xiaoyun Chai , Qingjie Zhao , Jishun Yang , Zhi Liu , Qingguo Meng , Yan Song
{"title":"Design, synthesis and anti-influenza A virus activity of N-containing heterocyclic glycyrrhetinic acid derivatives","authors":"Juan Zhang , Le Mi , Zhenwei Wang , Xiaohui Zhang , Xiaoyun Chai , Qingjie Zhao , Jishun Yang , Zhi Liu , Qingguo Meng , Yan Song","doi":"10.1016/j.bmcl.2025.130364","DOIUrl":"10.1016/j.bmcl.2025.130364","url":null,"abstract":"<div><div>Glycyrrhetinic acid (GA), a bioactive triterpenoid derived from <em>Glycyrrhiza glabra</em>, exhibits broad-spectrum antiviral properties but suffers from poor solubility and bioavailability. To enhance its anti-influenza activity, we designed and synthesized 12 novel nitrogen-containing heterocyclic GA derivatives through structural modifications at the A-ring (C-2/C-3) and C-30 position. All compounds were evaluated against influenza A/H1N1 virus in 293T cells. At 10 μM, 10 derivatives outperformed ribavirin, with compound <strong>12b</strong> (bearing an A-ring furazan and C-30 imidazole ester) showing the highest potency (IC<sub>50</sub> = 2.9 μM, selectivity index SI = 38.6) representing a 7.1-fold improvement over GA (IC<sub>50</sub> = 9.6 μM) and 3.7-fold superiority to ribavirin. Molecular docking revealed that <strong>12b</strong> binds strongly to neuraminidase (PDB:<span><span>1NN2</span><svg><path></path></svg></span>; binding energy: −8.11 kcal/mol) via hydrogen bonds with Glu413, Asp125, and Phe100, suggesting NA as a potential target. This study demonstrates that A-ring furazan modification combined with C-30 nitrogen-containing heterocyclic incorporation significantly enhances anti-influenza activity, providing a promising lead compound (<strong>12b</strong>) for further development.</div></div>","PeriodicalId":256,"journal":{"name":"Bioorganic & Medicinal Chemistry Letters","volume":"129 ","pages":"Article 130364"},"PeriodicalIF":2.2,"publicationDate":"2025-08-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144811416","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Zhongling Shi , Anchao Ge , Xin Li , Jinyuan Wu , Zhao Wang , Dongwei Kang , Xinyong Liu
{"title":"Recent advances of the respiratory syncytial virus inhibitors","authors":"Zhongling Shi , Anchao Ge , Xin Li , Jinyuan Wu , Zhao Wang , Dongwei Kang , Xinyong Liu","doi":"10.1016/j.bmcl.2025.130365","DOIUrl":"10.1016/j.bmcl.2025.130365","url":null,"abstract":"<div><div>Respiratory syncytial virus (RSV) remains a leading cause of severe lower respiratory tract infections in infants and the elderly, despite the lack of specific therapeutic drugs for treating RSV infection. This review summarizes recent structural advances in RSV drug discovery, particularly the <em>co</em>-crystal structures of the viral fusion (F) protein and RNA polymerase with inhibitors. By highlighting their significance in rational structure-based drug design, we hope to provide valuable insights for the development of next-generation RSV therapeutics via structure-based approaches.</div></div>","PeriodicalId":256,"journal":{"name":"Bioorganic & Medicinal Chemistry Letters","volume":"129 ","pages":"Article 130365"},"PeriodicalIF":2.2,"publicationDate":"2025-08-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144811417","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Connor M. Winkelhake , Binayak Rimal , Ben A. Thomas , Joe B. Huisken , Gyanu Lamichhane , J. Thomas Ippoliti
{"title":"Synthesis and antibacterial activity of novel benzodioxin-containing oxazolidinones against M. abscessus","authors":"Connor M. Winkelhake , Binayak Rimal , Ben A. Thomas , Joe B. Huisken , Gyanu Lamichhane , J. Thomas Ippoliti","doi":"10.1016/j.bmcl.2025.130359","DOIUrl":"10.1016/j.bmcl.2025.130359","url":null,"abstract":"<div><div><em>Mycobacterium abscessus</em> infections represent a significant treatment challenge, owing to the lack of effective therapies, and the intensive multidrug regimens currently recommended for this indication. Oxazolidinone antibiotics such as linezolid have been used to treat this complex disease. Utilizing a strategic structural extension strategy, five novel oxazolidinone derivatives were synthesized by the introduction of oxime, nitrile, amide, amidoxime, and oxime ester functional groups to a previously reported benzodioxin-scaffold. The <em>in vitro</em> activities of these derivatives against <em>M. abscessus</em> were assessed<em>,</em> with the amidoxime derivative exhibiting activity superior to linezolid.</div></div>","PeriodicalId":256,"journal":{"name":"Bioorganic & Medicinal Chemistry Letters","volume":"128 ","pages":"Article 130359"},"PeriodicalIF":2.2,"publicationDate":"2025-08-06","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144803051","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Suresh Chandra V.A.R. Annam , Ahmed Elbermawi , Jungmoo Huh , Jin Zhang , Zulfiqar Ali , Ikhlas A. Khan , Nirmal D. Pugh , Amar G. Chittiboyina
{"title":"In vitro anti-influenza potential of glyceroglycolipids from cyanobacteria Limnospira fusiformis","authors":"Suresh Chandra V.A.R. Annam , Ahmed Elbermawi , Jungmoo Huh , Jin Zhang , Zulfiqar Ali , Ikhlas A. Khan , Nirmal D. Pugh , Amar G. Chittiboyina","doi":"10.1016/j.bmcl.2025.130358","DOIUrl":"10.1016/j.bmcl.2025.130358","url":null,"abstract":"<div><div>Previously, a chemical standardization method quantifying six fatty acids was established for <em>Limnospira</em> (formerly <em>Arthrospira</em>) authenticity and quality control. Since glyceroglycolipids constitute a significant source of fatty acids in <em>Limnospira</em>, a targeted phytochemical investigation was performed that resulted in the identification of two novel diacylated glycerol sulfoquinvosides and four known compounds. Notably, <em>in vitro</em> anti-influenza activity of isolated and analogous glyceroglycolipids, specifically two glyceroglycolipids, incorporating γ-linolenic acid and sulfoquinvose units tethered to a glycerol backbone, exhibited the highest anti-influenza activity. These findings suggest that the glyceroglycolipid-enriched fraction from <em>Limnospira</em> holds the potential for direct-acting antiviral properties.</div></div>","PeriodicalId":256,"journal":{"name":"Bioorganic & Medicinal Chemistry Letters","volume":"128 ","pages":"Article 130358"},"PeriodicalIF":2.2,"publicationDate":"2025-08-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144774420","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}